ReviewNature reviews. Drug discovery2011
Novel therapeutic targets for the treatment of heart failure.
Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Trial
- Role of local angiotensin II signaling in bladder function.American journal of physiology. Renal physiology · 2024Review
- Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation.International journal of molecular sciences · 2023Review
- Photopolymerizable Hydrogel for Enhanced Intramyocardial Vascular Progenitor Cell Delivery and Post-Myocardial Infarction Healing.Advanced healthcare materials · 2023Article
- Exosomal circular RNAs: Biogenesis, effect, and application in cardiovascular diseases.Frontiers in cell and developmental biology · 2022Review
- The protective effect of isosteviol sodium on cardiac function and myocardial remodelling in transverse aortic constriction rat.Journal of cellular and molecular medicine · 2021Article
- Cardiac Gq Receptors and Calcineurin Activation Are Not Required for the Hypertrophic Response to Mechanical Left Ventricular Pressure Overload.Frontiers in cell and developmental biology · 2021Article
- I-Oxidative medicine and cellular longevity · 2021Article
- Bcl-2 Is Involved in Cardiac Hypertrophy through PI3K-Akt Pathway.BioMed research international · 2021Article
- Structure of the MICU1-MICU2 heterodimer provides insights into the gatekeeping threshold shift.IUCrJ · 2020Article
- Circular RNA-Expression Profiling Reveals a Potential Role of Hsa_circ_0097435 in Heart Failure via Sponging Multiple MicroRNAs.Frontiers in genetics · 2020Article
- Renin Activity in Heart Failure with Reduced Systolic Function-New Insights.International journal of molecular sciences · 2019Review
- ADAM23 in Cardiomyocyte Inhibits Cardiac Hypertrophy by Targeting FAK - AKT Signaling.Journal of the American Heart Association · 2018Article
- Flavonoid Extract from Propolis Inhibits Cardiac Fibrosis Triggered by Myocardial Infarction through Upregulation of SIRT1.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction.The Journal of experimental medicine · 2017Article
- Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.Molecular and cellular biochemistry · 2017Article
- Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration.Molecules (Basel, Switzerland) · 2017Review
- Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy.PloS one · 2017Article
- Adenosine ADrug design, development and therapy · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite considerable therapeutic advances, heart failure remains a medical and socioeconomic problem. Thus, there is a compelling need for new drugs that could improve clinical outcomes. In recent years, new potential therapeutic targets that are involved in the pathogenesis of heart failure have been identified, and new drugs are currently under investigation. A repeated finding is that the positive results that have been observed in preclinical studies and Phase II trials are not always confirmed in Phase III studies. This Review analyses the new therapeutic targets (for example, ventricular remodelling, renin-angiotensin-aldosterone system activation, defects in Ca(2+) cycling, and so on), the mechanism of action, efficacy and future perspectives of new drugs that are currently under development for the treatment of heart failure, and the possible explanations for the discrepancy between Phase II and Phase III trials.
Indexed as
Identifiers
21701502What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.